Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEDP -0.51%97 3-1 Month Momentum % is 27.91% as of Aug. 17, 2026. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $532.79 (Fairly Valued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 89.25% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Medpace Holdings's 3-1 Month Momentum % is 27.91%.
The industry rank for Medpace Holdings's 3-1 Month Momentum % or its related term are showing as below:
MEDP's 3-1 Month Momentum % is ranked better than 89.25% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.45
vs MEDP: 27.91
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Medpace Holdings 3-1 Month Momentum % Related Terms
MEDP vs GH, ICLR, RVTY: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEDP) has a 3-1 Month Momentum % of 27.91% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medpace Holdings and its competitors. According to the industry distribution chart, Medpace Holdings ranks #23 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 10.7%.
Is Medpace Holdings' 3-1 Month Momentum % too high?
Medpace Holdings' current 3-1 Month Momentum % is 27.91%. Based on the distribution chart, Medpace Holdings ranks #23 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' 3-1 Month Momentum % compare to GH and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #23 out of 214 companies for 3-1 Month Momentum %. This places Medpace Holdings in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current 3-1 Month Momentum % is 27.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $532.79, compared to a current price of $578.02 — trading 8.5% above its estimated fair value. The current 3-1 Month Momentum % is 27.91%. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current 3-1 Month Momentum % is 27.91% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $578.02 is trading 8.5% above its estimated GF Value™ of $532.79.
GuruFocus considers Medpace Holdings to be Fairly Valued.
Key valuation signals for MEDP:
3-1 Month Momentum %: 27.91%
GF Value™: $532.79 vs. price of $578.02 (8.5% above fair value)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score
Get the complete analysis for MEDP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
